Seems you have not registered as a member of localhost.saystem.shop!
You may have to register before you can download all our books and magazines, click the sign up button below to create a free account.
Tertiary Lymphoid Organs (TLOs): Powerhouses of Disease Immunity
The immune system employs TLOs to elicit highly localized and forceful responses to unresolvable peripheral tissue inflammation. Current data indicate that TLOs are protective but they may also lead to collateral tissue injury and serve as nesting places to generate autoreactive lymphocytes. A better comprehension of these powerhouses of disease immunity will likely facilitate development to unprecedented and specific therapies to fight chronic inflammatory diseases.
Tertiary Lymphoid Structures: from Basic Biology to Translational Impact in Cancer
description not available right now.
A year in review: Discussions in cancer immunity and immunotherapy
description not available right now.
Emerging Roles and Mechanisms of Stromal Cells in Carcinomas at the Molecular Level
description not available right now.
Defining the Spatial Organization of Immune Responses to Cancer and Viruses in situ
description not available right now.
Innate Immune Cell Therapy of Cancer
Adoptive cellular immunotherapy of cancer, particularly chimeric antigen receptor-transduced T cell (CAR-T) therapies, have enjoyed an explosion of clinical trials and translational and basic research in the past decade. The concept and design of the CAR, though originally intended to optimize targeting of innate natural killer cells (NK cells) to tumor-specific antigens, was laterally applied in the past decade to conventional autologous and later third-party allogeneic T cells with first-in-kind successes in leukemia immunotherapy in both adults and children. This approach also spawned the development of an entire industry focused on cancer immunotherapy, laying the foundation for the current paradigm shifts away from toxic chemo/radiotherapy to immune targeting. Aside from cytokine-release toxicities, specific obstacles plaguing existing CAR-T cell therapies include suboptimal killing by fatigued or senescent autologous patient-derived T cells derived, acquisition of tumor resistance to T-cell based immune therapies, and graft-versus-host disease (GVHD) associated with allogeneic conventional T cell therapies.
Community Series in Resident Memory T Cells: Guardians of the Balance of Local Immunity and Pathology, Volume II
As we learn more about the intricacies of immune interactions, the goalposts of ideal vaccination strategies change. It has become apparent that for many pathogens, immunizations should seek to optimize lymphocyte-mediated protection at their portals of entry, which is not likely to be accomplished with current intramuscular jabs. However, there are increased reports suggesting resident memory CD4 and CD8 T cells may, or indeed do, cause pathologies in the lung, gut, skin, pancreas, CNS, and adipose tissue. This is following chronic infection, immunization, or sensitization and it is becoming clearer that protective immunity ought to be finely balanced with the pathogenic capacity of the res...
Roles of Tumor-Recruited Myeloid Cells in Immune Evasion in Cancer
description not available right now.
Tumor Immunology and Immunotherapy - Cellular Methods Part B
Tumor Immunology and Immunotherapy - Cellular Methods Part B, Volume 632, the latest release in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Topics covered include Quantitation of calreticulin exposure associated with immunogenic cell death, Side-by-side comparisons of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death, Quantitative determination of phagocytosis by bone marrow-derived dendritic cells via imaging flow cytometry, Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies, Methods to assess DC-dependent priming of T cell responses by dying cells, and more.
